Stay updated with breaking news from Neil Kumar. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
BridgeBio Pharma Inc. is free of shareholder litigation over its $175 million buyout of Eidos Therapeutics Inc. after Delaware’s top court rejected self-dealing claims brought by a pension fund.
BridgeBio Pharma (NASDAQ:BBIO – Free Report) had its price objective lifted by BTIG Research from $32.00 to $42.00 in a research report released on Tuesday morning, FlyOnTheWall reports. Several other research firms have also commented on BBIO. Jefferies Financial Group lowered BridgeBio Pharma from a buy rating to a hold rating and upped their target […]
Jefferies Financial Group cut shares of BridgeBio Pharma (NASDAQ:BBIO – Free Report) from a buy rating to a hold rating in a research note published on Monday, Marketbeat reports. They currently have $33.00 price target on the stock, up from their prior price target of $24.00. The analysts noted that the move was a valuation […]
Ronald Daniels and some trustees at the Johns Hopkins University have outside board seats that prompted some critics to raise conflict-of-interest concerns.